{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026593","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.072605+00:00","generated_at":"2026-06-22T02:35:16.149423+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioCardia reports Q3 net loss $8.9M, DSMB supports adaptive design for heart failure trial","bullets":["9-month revenue $1.2M (up from $0.9M), net loss $8.9M, operating cash burn $7.6M.","CardiAMP heart failure trial DSMB recommends adaptive statistical plan for early readout; 100% survival at 2 years in roll-in cohort.","IND filed for NK1R+ MSC for heart failure (BCDA-03); FDA approval anticipated Dec 2022.","First manufacturing batch for ARDS program (BCDA-04) completed; first patient treatment expected Q4 2022.","BlueRock partnership for cell delivery; upfront payment received, option for worldwide license."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026593","json":"https://secwatch.observer/filing/0001437749-22-026593.json","markdown":"https://secwatch.observer/filing/0001437749-22-026593.md","text":"https://secwatch.observer/filing/0001437749-22-026593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774922026593/0001437749-22-026593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774922026593/bcda20221108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:35:16.149423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6275c63424d799785c496edd896a5ce7d839ebc2","claim":"BioCardia, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774922026593/0001437749-22-026593-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}